Influence of EMAP II, IFN-α2b and its medicinal preparations on the MGMT protein amount in human cells in vitro

• Дата: 2014
• Автори: Kotsarenko, K.V., Lylo, V.V., Ruban, T.P., Macewicz, L.L., Kornelyuk, A.I., Chernykh, S.I., Lukash, L.L.
• Формат: Стаття
• Мова: English
• Опубліковано: Інститут молекулярної біології і генетики НАН України 2014
• Назва видання: Вiopolymers and Cell
• Теми: Genomics, Transcriptomics and Proteomics
• Онлайн доступ: http://dspace.nbuv.gov.ua/handle/123456789/154591
• Назва журналу: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Цитувати: Influence of EMAP II, IFN-α2b and its medicinal preparations on the MGMT protein amount in human cells in vitro / K.V. Kotsarenko, V.V. Lylo, T.P. Ruban, L.L. Macewicz, A.I. Kornelyuk, S.I. Chernykh, L.L. Lukash // Вiopolymers and Cell. — 2014. — Т. 30, № 6. — С. 448-453. — Бібліогр.: 31 назв. — англ.

Aim. To study the effect of EMAP II, IFN-α2b and its medicinal preparations on the amount of O6-methylguanine-DNA methyltransferase (MGMT) protein in human cells in vitro. Methods. The human cells of 4BL and Hep-2 lines were treated with the purified recombinant proteins EMAP II, IFN-α2b and its commercial me dicinal preparations. Changes in the MGMT gene expression were studied at a protein level by Western blot analysis. Results. Treatment of Hep-2 and 4BL cells with EMAP II at the concentrations of 0.02 mg/ml and 2 mg/ml respectively led to induction of the MGMT gene expression. EMAP II at the concentrations of 0.2–20 g/ml caused decrease of the MGMT protein amount in Hep-2 cells. The regulating activity of EMAP II was also observed for MARP (anti-Methyltransferase Antibody Recognizable Protein). IFN-α2b and Laferon-PharmBiotek with the activity of 200 and 2000 IU/ml were shown to cause an increase of the MGMT protein amount in Hep-2 cells. Conclusions. The purified recombinant proteins EMAP II and IFN-α2b which are substrates for the medicinal preparations influenced on the amount of MGMT protein in the human cell cultures in a concentration-dependent manner. At the same time the effect of medicinal preparations differs from that of the purified protein IFN-α2b. Possibly it depends on the presence of stabilizing components in their compositions.